BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 34681959)

  • 1. Stimulus-Responsive Smart Nanoparticles-Based CRISPR-Cas Delivery for Therapeutic Genome Editing.
    Naeem M; Hoque MZ; Ovais M; Basheer C; Ahmad I
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
    Cai W; Luo T; Mao L; Wang M
    Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smart Strategies for Precise Delivery of CRISPR/Cas9 in Genome Editing.
    Hasanzadeh A; Noori H; Jahandideh A; Haeri Moghaddam N; Kamrani Mousavi SM; Nourizadeh H; Saeedi S; Karimi M; Hamblin MR
    ACS Appl Bio Mater; 2022 Feb; 5(2):413-437. PubMed ID: 35040621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
    Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
    AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing.
    Tang H; Zhao X; Jiang X
    Adv Drug Deliv Rev; 2021 Jan; 168():55-78. PubMed ID: 32147450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.
    Liu J; Chang J; Jiang Y; Meng X; Sun T; Mao L; Xu Q; Wang M
    Adv Mater; 2019 Aug; 31(33):e1902575. PubMed ID: 31215123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
    Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
    Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering the Delivery System for CRISPR-Based Genome Editing.
    Glass Z; Lee M; Li Y; Xu Q
    Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External stimuli-responsive nanoparticles for spatially and temporally controlled delivery of CRISPR-Cas genome editors.
    Xie R; Wang Y; Gong S
    Biomater Sci; 2021 Sep; 9(18):6012-6022. PubMed ID: 34286726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing.
    Fang T; Cao X; Ibnat M; Chen G
    J Nanobiotechnology; 2022 Aug; 20(1):354. PubMed ID: 35918694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
    Zhang S; Shen J; Li D; Cheng Y
    Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
    Chen F; Alphonse M; Liu Q
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
    He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
    Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in stimuli-responsive polymeric carriers for controllable CRISPR/Cas9 gene editing system delivery.
    Ma P; Wang Q; Luo X; Mao L; Wang Z; Ye E; Loh XJ; Li Z; Wu YL
    Biomater Sci; 2023 Jul; 11(15):5078-5094. PubMed ID: 37282836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sono-Controllable and ROS-Sensitive CRISPR-Cas9 Genome Editing for Augmented/Synergistic Ultrasound Tumor Nanotherapy.
    Pu Y; Yin H; Dong C; Xiang H; Wu W; Zhou B; Du D; Chen Y; Xu H
    Adv Mater; 2021 Nov; 33(45):e2104641. PubMed ID: 34536041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
    Xu Y; Liu R; Dai Z
    Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.